Literature DB >> 25773225

Neurology issues in schizophrenia.

Katharina Hüfner1, Beatrice Frajo-Apor, Alex Hofer.   

Abstract

Schizophrenia ranks among the leading causes of disability worldwide. The presence of neurological signs co-occurring with the psychiatric symptoms is indicative of an organic brain pathology. In the present article, we review the current literature on neurology issues in schizophrenia. Firstly, common neurological signs found in patients with schizophrenia (neurological soft signs and smell abnormalities) and their association with imaging findings are reviewed. Secondly, the significant association of schizophrenia with epilepsy and stroke is described as well as the absent association with other organic brain diseases such as multiple sclerosis. Thirdly, we discuss the potential role of NMDA receptor antibodies in schizophrenia. Fourthly, neurological side effects of antipsychotic drugs and their treatment are reviewed; and lastly, we discuss neurocognitive deficits in patients with schizophrenia and their treatment. The focus of the review remains on articles with relevance to the clinician.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25773225     DOI: 10.1007/s11920-015-0570-4

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  62 in total

1.  Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Authors:  Douglas L Boggs; Deanna L Kelly; Robert P McMahon; James M Gold; David A Gorelick; Jared Linthicum; Robert R Conley; Fang Liu; James Waltz; Marilyn A Huestis; Robert W Buchanan
Journal:  Schizophr Res       Date:  2011-12-03       Impact factor: 4.939

2.  Olfactory perception in schizophrenia: the rating range for hedonic judgements is increased during acute episodes.

Authors:  Marion Clepce; Karin Reich; Andrea Gossler; Johannes Kornhuber; Norbert Thuerauf
Journal:  Psychiatry Res       Date:  2012-10-22       Impact factor: 3.222

3.  Odor hedonic capacity and anhedonia in schizophrenia and unaffected first-degree relatives of schizophrenia patients.

Authors:  Vidyulata Kamath; Paul J Moberg; Christian G Kohler; Raquel E Gur; Bruce I Turetsky
Journal:  Schizophr Bull       Date:  2011-05-26       Impact factor: 9.306

4.  Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia.

Authors:  Melissa Fisher; Rachel Loewy; Cameron Carter; Ashley Lee; J Daniel Ragland; Tara Niendam; Danielle Schlosser; Lien Pham; Tara Miskovich; Sophia Vinogradov
Journal:  Schizophr Bull       Date:  2014-01-20       Impact factor: 9.306

5.  Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study.

Authors:  Chun-Hui Liao; Chen-Shu Chang; Wan-Ching Wei; Shih-Ni Chang; Chien-Chang Liao; Hsien-Yuan Lane; Fung-Chang Sung
Journal:  Schizophr Res       Date:  2011-01-08       Impact factor: 4.939

Review 6.  Obstructive sleep apnoea and schizophrenia--a research agenda.

Authors:  Megan J Kalucy; Ron Grunstein; Timothy Lambert; Nicholas Glozier
Journal:  Sleep Med Rev       Date:  2013-03-23       Impact factor: 11.609

Review 7.  [Neurological soft signs as a candidate for endophenotype of schizophrenia].

Authors:  Olga Kałuzyńska; Jolanta Rabe-Jabłońska
Journal:  Psychiatr Pol       Date:  2014 Jan-Feb       Impact factor: 1.657

8.  A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

Authors:  Jeffrey A Lieberman; Geoffrey Dunbar; Anthony C Segreti; Ragy R Girgis; Frances Seoane; Jessica S Beaver; Naihua Duan; David A Hosford
Journal:  Neuropsychopharmacology       Date:  2012-12-18       Impact factor: 7.853

9.  Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions.

Authors:  Dieter Schoepf; Hardeep Uppal; Rahul Potluri; Reinhard Heun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-08-13       Impact factor: 5.270

Review 10.  Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis.

Authors:  T A Pollak; R McCormack; M Peakman; T R Nicholson; A S David
Journal:  Psychol Med       Date:  2013-12-13       Impact factor: 7.723

View more
  5 in total

1.  MicroRNA-29 is an essential regulator of brain maturation through regulation of CH methylation.

Authors:  Vijay Swahari; Ayumi Nakamura; Emilie Hollville; Hume Stroud; Jeremy M Simon; Travis S Ptacek; Matthew V Beck; Cornelius Flowers; Jiami Guo; Charlotte Plestant; Jie Liang; C Lisa Kurtz; Matt Kanke; Scott M Hammond; You-Wen He; E S Anton; Praveen Sethupathy; Sheryl S Moy; Michael E Greenberg; Mohanish Deshmukh
Journal:  Cell Rep       Date:  2021-04-06       Impact factor: 9.423

2.  Chronic Neuropsychological Sequelae in a Patient with Nontumorous Anti-NMDA-Receptor Encephalitis.

Authors:  Dong Y Han; Lisa M Koehl; Aarti Patel; Zhengqiu Zhou; Sarah Phillips; Siddharth Kapoor
Journal:  Case Rep Neurol Med       Date:  2017-04-19

3.  Distinct pattern of cerebral blood flow alterations specific to schizophrenics experiencing auditory verbal hallucinations with and without insight: a pilot study.

Authors:  Rixing Jing; Jiangjie Huang; Deguo Jiang; Xiaodong Lin; Xiaolei Ma; Hongjun Tian; Jie Li; Chuanjun Zhuo
Journal:  Oncotarget       Date:  2017-12-23

4.  Physical Comorbidity According to Diagnoses and Sex among Psychiatric Inpatients in South Korea.

Authors:  Suin Park; Go-Un Kim; Hyunlye Kim
Journal:  Int J Environ Res Public Health       Date:  2021-04-15       Impact factor: 3.390

5.  Propionate Protects Haloperidol-Induced Neurite Lesions Mediated by Neuropeptide Y.

Authors:  Minmin Hu; Peng Zheng; Yuanyi Xie; Zehra Boz; Yinghua Yu; Renxian Tang; Alison Jones; Kuiyang Zheng; Xu-Feng Huang
Journal:  Front Neurosci       Date:  2018-10-15       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.